[{"id":"8fac6d48-bf25-4ede-b0bd-19869334e342","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472140","created_at":"2026-03-28T01:41:57.184Z","updated_at":"2026-03-28T01:41:57.184Z","phase":"Phase 2/3","brief_title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT07472140","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"df568c08-818e-4e88-a7ec-38377deb4c56","acronym":"","url":"https://clinicaltrials.gov/study/NCT07162051","created_at":"2025-09-13T08:42:14.196Z","updated_at":"2025-09-13T08:42:14.196Z","phase":"Phase 2","brief_title":"A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT07162051","lead_sponsor":"Xijing Hospital","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cyclophosphamide • AiRuiYi (fluzoparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-09-09"},{"id":"264b6c87-54a5-4e3b-9928-8b444e1c65f6","acronym":"ROYAL","url":"https://clinicaltrials.gov/study/NCT07151911","created_at":"2025-09-06T13:40:25.560Z","updated_at":"2025-09-06T13:40:25.560Z","phase":"","brief_title":"Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients","source_id_and_acronym":"NCT07151911 - ROYAL","lead_sponsor":"Azienda Ospedaliero-Universitaria di Modena","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/26/2024","start_date":" 08/26/2024","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2031","study_completion_date":" 09/01/2031","last_update_posted":"2025-09-03"},{"id":"c72ecd8f-9c23-45c8-aceb-c2281207ef26","acronym":"","url":"https://clinicaltrials.gov/study/NCT07141771","created_at":"2025-08-30T13:51:58.696Z","updated_at":"2025-08-30T13:51:58.696Z","phase":"Phase 1/2","brief_title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","source_id_and_acronym":"NCT07141771","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • etoposide IV • irinotecan • topotecan • AiRuiYi (fluzoparib) • Zepzelca (lurbinectedin) • Hetronifly (serplulimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/31/2025","start_date":" 12/31/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-08-26"},{"id":"5ab70206-a4cc-4b5d-b4d4-1bcadd6d07f9","acronym":"BR-OLP-CT-101","url":"https://clinicaltrials.gov/study/NCT07069335","created_at":"2025-07-19T14:11:52.627Z","updated_at":"2025-07-19T14:11:52.627Z","phase":"Phase 1","brief_title":"A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer","source_id_and_acronym":"NCT07069335 - BR-OLP-CT-101","lead_sponsor":"Boryung Pharmaceutical Co., Ltd","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/17/2025","start_date":" 06/17/2025","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-07-16"},{"id":"2360563a-7ee0-45bc-b686-a50af2502a4a","acronym":"DAPA-ARMOR","url":"https://clinicaltrials.gov/study/NCT07018622","created_at":"2025-06-14T13:56:13.578Z","updated_at":"2025-06-14T13:56:13.578Z","phase":"Phase 2","brief_title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","source_id_and_acronym":"NCT07018622 - DAPA-ARMOR","lead_sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","biomarkers":" B2M","pipe":"","alterations":" ","tags":["B2M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin • carboplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 05/07/2025","start_date":" 05/07/2025","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2025-06-12"},{"id":"d7a65642-897e-45bd-94d5-4d6f95fb2fdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856499","created_at":"2025-06-07T14:55:53.232Z","updated_at":"2025-06-07T14:55:53.232Z","phase":"Phase 1","brief_title":"Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer","source_id_and_acronym":"NCT06856499","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cirtuvivint (SM08502)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2025-05-28"},{"id":"2a09abe0-6495-491d-a75a-5fe8da47ac10","acronym":"","url":"https://clinicaltrials.gov/study/NCT04086485","created_at":"2021-01-18T20:00:12.098Z","updated_at":"2025-02-25T12:27:19.621Z","phase":"Phase 1/2","brief_title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","source_id_and_acronym":"NCT04086485","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["BRCA • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/03/2022","start_date":" 10/03/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-24"},{"id":"67ef8418-6d77-4d74-95d8-80f63ef20ed4","acronym":"SWOG S2001","url":"https://clinicaltrials.gov/study/NCT04548752","created_at":"2021-01-18T21:45:16.998Z","updated_at":"2025-02-25T12:27:43.236Z","phase":"Phase 2","brief_title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","source_id_and_acronym":"NCT04548752 - SWOG S2001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • cisplatin • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-24"},{"id":"79649cc6-d582-4cf7-94a7-6b84b6103cab","acronym":"","url":"https://clinicaltrials.gov/study/NCT04901702","created_at":"2021-05-25T18:52:49.387Z","updated_at":"2025-02-25T12:28:07.986Z","phase":"Phase 1/2","brief_title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","source_id_and_acronym":"NCT04901702","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" EWSR1 • FLI1","pipe":"","alterations":" ","tags":["EWSR1 • FLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Talzenna (talazoparib) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/09/2021","start_date":" 06/09/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"5ca3f586-5d57-495c-9088-bac9d19c4782","acronym":"","url":"https://clinicaltrials.gov/study/NCT04826341","created_at":"2021-04-01T16:52:34.686Z","updated_at":"2025-02-25T13:40:26.267Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","source_id_and_acronym":"NCT04826341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A","pipe":" | ","alterations":" ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation","tags":["BRCA1 • BRCA2 • HRD • CDK12 • BRCA • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • RAD54L • FANCL • PPP2R2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • RAD54L mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/20/2021","start_date":" 09/20/2021","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2025-02-21"},{"id":"7db8cbc0-f928-4935-a5eb-7dd8dd21f64b","acronym":"EA2192","url":"https://clinicaltrials.gov/study/NCT04858334","created_at":"2021-04-26T13:52:59.130Z","updated_at":"2025-02-25T13:40:27.622Z","phase":"Phase 2","brief_title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","source_id_and_acronym":"NCT04858334 - EA2192","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" PALB2 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PALB2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-21"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"4cc7d5ae-d434-4c5a-bf92-880e3c64f923","acronym":"NCI-2016-01130","url":"https://clinicaltrials.gov/study/NCT02849496","created_at":"2021-01-18T13:59:18.008Z","updated_at":"2025-02-25T13:52:10.914Z","phase":"Phase 2","brief_title":"Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer","source_id_and_acronym":"NCT02849496 - NCI-2016-01130","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TMB • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 positive • BRCA mutation","tags":["HER-2 • TMB • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Tecentriq (atezolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/30/2017","start_date":" 03/30/2017","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-20"},{"id":"5b783b7c-5a42-40ed-b63a-61150837a02a","acronym":"A021804","url":"https://clinicaltrials.gov/study/NCT04394858","created_at":"2021-01-29T07:20:43.079Z","updated_at":"2025-02-25T13:53:17.999Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","source_id_and_acronym":"NCT04394858 - A021804","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MGMT • CD4","pipe":"","alterations":" ","tags":["MGMT • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • temozolomide"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-20"},{"id":"5eb63239-f0c2-440d-925c-994f2877adc9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00740805","created_at":"2021-01-18T02:47:51.919Z","updated_at":"2025-02-25T13:47:58.987Z","phase":"Phase 1","brief_title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT00740805","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR • BRCA1 • BRCA","pipe":" | ","alterations":" HER-2 negative • BRCA mutation","tags":["HER-2 • ER • PGR • BRCA1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 08/18/2008","start_date":" 08/18/2008","primary_txt":" Primary completion: 09/03/2021","primary_completion_date":" 09/03/2021","study_txt":" Completion: 10/22/2025","study_completion_date":" 10/22/2025","last_update_posted":"2025-02-20"},{"id":"9746c38a-e183-480a-bcc4-ea83361a9977","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554328","created_at":"2022-09-26T14:56:09.383Z","updated_at":"2025-02-25T13:49:33.072Z","phase":"Phase 2","brief_title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","source_id_and_acronym":"NCT05554328","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation","tags":["KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Koselugo (selumetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-20"},{"id":"a7bc76a3-7767-4569-b28f-313c198056ba","acronym":"MAGNITUDE","url":"https://clinicaltrials.gov/study/NCT03748641","created_at":"2021-01-18T18:22:54.153Z","updated_at":"2025-02-25T13:52:43.687Z","phase":"Phase 3","brief_title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03748641 - MAGNITUDE","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" HRD • BRCA","pipe":"","alterations":" ","tags":["HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • abiraterone acetate • prednisone • Akeega (abiraterone/niraparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 765","initiation":"Initiation: 01/25/2019","start_date":" 01/25/2019","primary_txt":" Primary completion: 10/08/2021","primary_completion_date":" 10/08/2021","study_txt":" Completion: 03/19/2027","study_completion_date":" 03/19/2027","last_update_posted":"2025-02-20"},{"id":"b94d3fe3-9040-4df9-8c37-231f34f9f98f","acronym":"POLESTAR","url":"https://clinicaltrials.gov/study/NCT05268510","created_at":"2022-03-07T18:53:55.391Z","updated_at":"2025-02-25T13:54:16.446Z","phase":"Phase 2","brief_title":"Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib As Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma","source_id_and_acronym":"NCT05268510 - POLESTAR","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","biomarkers":" HER-2 • PD-L1 • CD8 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • oxaliplatin"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/15/2022","start_date":" 09/15/2022","primary_txt":" Primary completion: 08/27/2024","primary_completion_date":" 08/27/2024","study_txt":" Completion: 01/09/2025","study_completion_date":" 01/09/2025","last_update_posted":"2025-02-20"},{"id":"94997e45-2dee-4e97-9985-6f9da960c39e","acronym":"BROCADE3","url":"https://clinicaltrials.gov/study/NCT02163694","created_at":"2021-01-17T17:32:00.170Z","updated_at":"2025-02-25T14:06:48.816Z","phase":"Phase 3","brief_title":"A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer","source_id_and_acronym":"NCT02163694 - BROCADE3","lead_sponsor":"AbbVie","biomarkers":" HER-2 • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • veliparib (ABT-888)"],"overall_status":"Completed","enrollment":" Enrollment 513","initiation":"Initiation: 04/08/2014","start_date":" 04/08/2014","primary_txt":" Primary completion: 04/05/2019","primary_completion_date":" 04/05/2019","study_txt":" Completion: 01/25/2024","study_completion_date":" 01/25/2024","last_update_posted":"2025-02-19"},{"id":"f7e6df94-a121-41c2-ab20-30322990863a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05327010","created_at":"2022-04-14T12:53:52.597Z","updated_at":"2025-02-25T14:02:49.505Z","phase":"Phase 2","brief_title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","source_id_and_acronym":"NCT05327010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2025-02-19"},{"id":"3b6e3d94-f722-44f3-897f-bf1317cea5d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672095","created_at":"2023-01-05T14:58:27.769Z","updated_at":"2025-02-25T14:09:21.750Z","phase":"Phase 1/2","brief_title":"Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer","source_id_and_acronym":"NCT05672095","lead_sponsor":"City of Hope Medical Center","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA wild-type","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/18/2025","start_date":" 04/18/2025","primary_txt":" Primary completion: 11/27/2026","primary_completion_date":" 11/27/2026","study_txt":" Completion: 11/27/2026","study_completion_date":" 11/27/2026","last_update_posted":"2025-02-18"},{"id":"48f5abe6-9ec9-4e35-ad4a-60d366e60af6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03598257","created_at":"2021-01-18T17:41:27.688Z","updated_at":"2025-02-25T14:15:11.919Z","phase":"Phase 2","brief_title":"Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer","source_id_and_acronym":"NCT03598257","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-17"},{"id":"ab61b8a8-7577-42c8-aace-25d2ec073ed7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05700721","created_at":"2023-01-26T15:02:55.768Z","updated_at":"2025-02-25T14:09:25.231Z","phase":"Phase 2","brief_title":"Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)","source_id_and_acronym":"NCT05700721","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • HRD • CDK12 • CHEK2 • RAD51 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • RAD54L • FANCL • RAD52"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 08/07/2025","primary_completion_date":" 08/07/2025","study_txt":" Completion: 08/07/2027","study_completion_date":" 08/07/2027","last_update_posted":"2025-02-17"}]